Abstract:Presently, clinically approved adjuvants (such as aluminum salts) fail to induce cellular immune responses, which is crucial to defend against intracellular pathogens (including HIV, malaria, tuberculosis and Ebola) and cancer. However, Freund's complete adjuvant potently stimulates both humoral and cellular immune responses, accompanying by high toxicity and severe side reactions. Here in this work, a CpG-oligodeoxynucleotides (CpG-OND) crosslinked aminated beta-glucan-Ovalbumin dual targeting nanoparticle (CpG-OND-AG-OVA) is prepared through a simple and mild ionic complexation method. The aminated beta-glucan plays dual roles as antigen presenting cells (APCs) targeted carrier and immunopotentiator (targeting and activating dectin-1 on APCs). Meanwhile, CpG-OND also plays dual roles as ionic crosslinker and immunopotentiator (targeting and activating Toll-like receptor 9 in APCs). The adjuvant activity of the particles is evaluated through in vitro and in vivo experiments. The particles significantly enhance uptake and sustained proteolytic processing of antigens, and result in APCs maturation, inducing robust Th1 and Th2-type immune responses comparable to Freund's adjuvant without obvious toxicity. The potent adjuvant activity of the nanoparticles may originate from dual targeting synergistic effects between aminated beta-glucan and CpG-OND. Accordingly, the dual targeting nanoparticles may be a promising vaccine adjuvant for inducing robust humoral and cellular immune responses against infectious diseases and cancers. Statement of Significance An ideal adjuvant for subunit vaccine should act as both a carrier to enhance the uptake, sustained processing and cytosolic delivery of antigens, and an immunopotentiator to stimulate antigen presenting cells (APCs) for activation of naive T cells. Additionally, it should be easy to obtain and safe with negligible toxicity. Unfortunately, both synthetic and natural polymers that have been developed into antigen delivery system cannot completely fulfill the requirements. In the present study, the authors design nanoparticles with aminated beta-glucan and CpG-oligodeoxynucleotides (CpG-OND) through a simple and mild method. beta-Glucan (a dectin-1 and TLR2 targeted PAMP) and CpG-OND (a TLR9 targeted PAMP) are readily accessible. Aminated beta-glucan plays dual roles in the nanoparticle as APCs targeted carrier and immunopotentiator. Meanwhile, CpG-OND also plays dual roles as crosslinker and APCs targeted immunopotentiator. By making use of synergistic effect of the dual targeting vaccine adjuvant with aminated beta-glucan and CpG-OND, the nanoparticles induce robust antigen specific immune responses comparable to Freund's adjuvant without obvious toxicity. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes

Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro

Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice

Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses

Adjuvants and immune enhancement

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination

TLR9 and STING Agonists Cooperatively Boost the Immune Response to SARS-CoV-2 RBD Vaccine Through an Increased Germinal Center B Cell Response and Reshaped T Helper Responses

Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines

Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines

Co-adjuvanting Nod2-stimulating bacteria with a TLR7 agonist elicits potent protective immunity against respiratory virus infection

Synthetic Innate Defense Regulator Peptide Combination Using Cpg Odn As A Novel Adjuvant Induces Long-Lasting and Balanced Immune Responses

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response

Combined nanoemulsion and RIG-I agonist adjuvants-activation of diverse pathways for a broad spectrum influenza vaccine.

Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures

Synergistic Effect of Dual Targeting Vaccine Adjuvant with Aminated Β-Glucan and CpG-oligodeoxynucleotides for Both Humoral and Cellular Immune Responses

DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination

Human Innate Responses and Adjuvant Activity of TLR Ligands in Vivo in Mice Reconstituted with a Human Immune System.

Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations